Seladelpar for PBC moves to phase 3 following positive safety results

CymaBay Therapeutics achieved its targeted patient enrollment for the EHANCE trial, a phase 3 study of seladelpar for primary biliary cholangitis, and that the company is on track to complete full enrollment by the end of November.“Reaching the recruitment goal of our phase 3 study ahead of schedule underscores the enormous unmet need for new treatment options in this serious, chronic liver disease,” Sujal Shah, president and CEO of CymaBay Therapeutics, said in the press release. “I am proud of our team’s efforts, which are focused every day on delivering for patientsRead More

Share on facebook
Share on twitter
Share on linkedin